ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept). The drug was ...

Sandoz has filed an antitrust lawsuit in the US against Amgen, challenging alleged anti-competitive practices surrounding the biologic blockbuster Enbrel (etanercept). Filed at the US District ...

ZURICH, April 14 (Reuters) - Swiss generic drug manufacturer Sandoz (SDZ.S), opens new tab said on Monday it had filed an antitrust lawsuit in the United States against Amgen (AMGN.O), opens new ...

Sandoz Group AG reported a 3% increase in net sales for the first quarter of 2025, driven by a strong performance in its biosimilars segment, which now constitutes 27% of total net sales.

Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to develop and ...

LONDON, April 28 (Reuters) - The chief executive of generic drugmaker Sandoz (SDZ.S), opens new tab said a proposal by the CEOs of Novartis (NOVN.S), opens new tab and Sanofi (SASY.PA), opens new ...

ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz (SIX:SDZ) said on Monday it had filed an antitrust lawsuit in the United States against Amgen (NASDAQ:AMGN) over the alleged entrenchment ...

Richard Saynor, Chief Executive Officer of Sandoz, commented: “With Q1 sales in line with our expectations, we have now delivered fourteen consecutive quarters of top-line growth. This ...

Hoping to alter the timetable is Swiss generics and biosimilars specialist Sandoz, which has filed an antitrust lawsuit in federal court in Virginia claiming that Amgen has blocked competition to ...

Etanercept is a biologic medicine used to treat various inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz ...

Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab ...